Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: Rocketman who wrote (1396)	11/12/1998 8:23:00 PM
From: Mr. Miller	Respond to of 2135

Spins? I did not hear anyone complain about this statement from the NCI release on September 14th: Dr. James Pluda, Senior Clinical Investigator for the National Cancer Institute, commented on Endostatin(TM) research, ''The NCI is pleased to be collaborating with EntreMed on an antiangiogenic agent with the potential that Endostatin(TM) has demonstrated preclinically.'' ******************************************************** I know the NCI would not make this statement without believing this protein did what was said before. Today's WSJ report does not change this at all. We are closer to starting human trials in 1999. That, in itself, is amazing. The fact that this is being talked about so early demonstrates the impressive potential that this protein has for cancer patients. AND, the FDA does its best to get these drugs from the bench to the bedside as fast as their guidelines will allow and faster if the science is so compelling. Cancer patients are waiting for anything new that shows promise, and this science just makes sense. Tomorrow is going to be big. The CEO really has a chance to reignite this stock. FYI-I worked for the National Institute of Environmental Health Sciences--> a division of the National Institutes of Health. Miller